Although the SEC told Congress it was doing what it could to ramp up the rulemaking process to implement the Jumpstart Our Business Startups (JOBS) Act, it missed its first deadline. The SEC had until July 4, to release proposed rules to remove the ban against general solicitation and advertising in offerings conducted under Rule 506 of Regulation D and Rule 144A of the Securities Act.

The FDA is giving drugmakers 45 days to stop making unapproved single-ingredient, immediate-release oxycodone drugs in oral dosage forms, including tablets, capsules and oral solutions. They have 90 days to stop shipping them, according to a notice published in the Federal Register.